SIETES :: 92880 citas

Resultados de la búsqueda por Ross,JS REFINAR BÚSQUEDA

1.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D spending on single-enantiomer drugs versus their racemic precursors . Ann Intern Med 2019:13 de agosto. [Ref.ID 103162]

2.

Wallach JD, Eqilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ 2018;361:24 de mayo. [Ref.ID 102886]

3.

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]

4.

Puthumana J, Wallach JD, Ross JS. Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation. JAMA 2018;319:17 de julio. [Ref.ID 102793]

5.

Wallach JD, Ross JS. Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA 2018;319:27 de febrero. [Ref.ID 102781]

6.

Ross JS, Krumholz HM, Hines Jr HH. Bringing Vioxx back to market. BMJ 2018;360:k242. [Ref.ID 102639]

7.

Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]

8.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

9.

Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]

10.

Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2017;40:468-75. [Ref.ID 101507]

11.

Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016:septiembre. [Ref.ID 100915]

12.

Lee TC, Desforges P, Downing N, Greene J, Ross JS. Off-label use of quetiapine in medical inpatients and postdischarge. JAMA Intern Med 2016;176:1390-1. [Ref.ID 100752]

13.

Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189. [Ref.ID 100605]

14.

Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM, Hines HH. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016;352:i637. [Ref.ID 100065]

15.

Ross JS. Global drug safety insights from Taiwan. JAMA Intern Med 2015;175:Noviembre. [Ref.ID 99549]

16.

Ross JS, Redberg RF. On chlorofluorocarbon bans and inhaled albuterol prices. JAMA 2015;175:julio. [Ref.ID 99042]

17.

Lipska KJ, Ross JS, MIao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015;175:356-62. [Ref.ID 98764]

18.

Smithy JW, Downing NS, Ross JS. Publication of pivotal efficacy trials for novel therapeutics agents approved between 2005 and 2011: a cross-sectional study. JAMA Intern Med 2014;174:1518. [Ref.ID 97912]

19.

Ross JS, Frazee SG, Garavaglia SB, Levin R, Novshadian H, Jackevicius CA, Stettin G, Krumholz HM. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. JAMA Intern Med 2014;174:1486-93. [Ref.ID 97900]

20.

Ross JS, Kesselheim AS. Prescription-drug coupons - No such thing as a free lunch. N Engl J Med 2013;369:1188-9. [Ref.ID 96300]